MiMedx Group Inc (MDXG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MiMedx Group Inc (MDXG) has a cash flow conversion efficiency ratio of 0.123x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($29.33 Million) by net assets ($238.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MDXG company net worth for the company's overall valuation and market capitalisation.
MiMedx Group Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MiMedx Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MiMedx Group Inc ranked by their cash flow conversion efficiency. Explore MiMedx Group Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daheng New Epoch Technology Inc
SHG:600288
|
0.025x |
|
WESTROCK COFFEE CL.A
F:V3J
|
0.135x |
|
Latitude Group Holdings Ltd
AU:LFS
|
-0.165x |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
0.336x |
|
Birla Corporation Limited
NSE:BIRLACORPN
|
0.030x |
|
Baida Group Co Ltd
SHG:600865
|
0.003x |
|
Enghouse Systems Ltd
TO:ENGH
|
0.032x |
|
LiJiang YuLong Tourism Co Ltd
SHE:002033
|
0.071x |
Annual Cash Flow Conversion Efficiency for MiMedx Group Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of MiMedx Group Inc from 2006 to 2024. View MDXG live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $193.11 Million | $66.20 Million | 0.343x | +82.72% |
| 2023-12-31 | $142.72 Million | $26.77 Million | 0.188x | +178.12% |
| 2022-12-31 | $74.51 Million | $-17.89 Million | -0.240x | -1021.73% |
| 2021-12-31 | $92.58 Million | $-1.98 Million | -0.021x | +95.03% |
| 2020-12-31 | $91.42 Million | $-39.41 Million | -0.431x | -159.80% |
| 2019-12-31 | $49.66 Million | $35.80 Million | 0.721x | 0.00% |
| 2018-12-31 | $49.66 Million | $35.80 Million | 0.721x | -15.47% |
| 2017-12-31 | $73.80 Million | $62.94 Million | 0.853x | +339.18% |
| 2016-12-31 | $133.00 Million | $25.83 Million | 0.194x | +11.51% |
| 2015-12-31 | $107.99 Million | $18.81 Million | 0.174x | -7.41% |
| 2014-12-31 | $89.33 Million | $16.80 Million | 0.188x | +4947.15% |
| 2013-12-31 | $73.57 Million | $-285.48K | -0.004x | +97.71% |
| 2012-12-31 | $20.01 Million | $-3.38 Million | -0.169x | +69.80% |
| 2011-12-31 | $11.90 Million | $-6.66 Million | -0.560x | +58.10% |
| 2010-12-31 | $6.10 Million | $-8.16 Million | -1.337x | +5.10% |
| 2009-12-31 | $6.07 Million | $-8.56 Million | -1.409x | -146.44% |
| 2008-12-31 | $14.23 Million | $-8.14 Million | -0.572x | -186.00% |
| 2007-12-31 | $-35.60K | $-23.67K | 0.665x | +109.17% |
| 2006-12-31 | $3.26K | $-23.65K | -7.250x | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more